Nanovery

Nanovery is an early-stage biotech company developing a unique, enzyme-free diagnostic platform based on programmable DNA nanorobots. Its technology aims to directly and quantitatively detect short nucleic acid targets like ASOs, siRNAs, and miRNAs with minimal sample preparation and standard lab equipment. The company is initially targeting the research and bioanalysis market for RNA therapeutics, with a value proposition centered on simplicity, speed, and cost reduction compared to conventional methods like qPCR. As a private, likely pre-revenue entity, Nanovery is focused on assay development services and platform validation.

Nucleic Acid Nanorobotics (NANs): An enzyme-free, isothermal platform using programmable synthetic DNA nanostructures ('nanorobots') to detect and quantify specific nucleic acid sequences. It requires minimal sample prep, works in complex media, and uses a fluorescent readout on standard plate readers.

Nanovery competes in the nucleic acid detection space against established qPCR and hybridization assay providers, as well as a wave of newer technologies like CRISPR-based diagnostics (e.g., Sherlock Biosciences, Mammoth Biosciences) and other isothermal amplification methods (e.g., LAMP, RPA). Its differentiation hinges on being enzyme-free, simple, and leveraging dynamic DNA nanotechnology.